Priscilla Huang, Olivia Supan, Cecilia L Pak, Rahul C Mehta, Elizabeth T Makino
Background: The SkinMedica Acne Treatment Platform (SM Regimen) was formulated to treat acne without overdrying the skin. We evaluated efficacy and tolerability of the SM Regimen (including a novel 1% salicylic acid Acne Clarifying Cleanser and 2% salicylic acid Acne Treatment Lotion) versus a prescription formulation (Rx Regimen; including adapalene 0.1%/benzoyl peroxide 2.5%) in a diverse population of adults with mild to moderate facial acne.
Methods: This single-center, double-blind, randomized study enrolled adults (18-45 years) with Fitzpatrick skin types (FST) I-VI. SM Regimen or Rx Regimen was applied topically to the entire face for 12 weeks. Assessments were conducted at 24 and 48 h and 4, 8, and 12 weeks.
Results: Subjects (SM Regimen, n = 31; Rx Regimen, n = 23) were primarily female (90.7%) with mean age of 28.6 years; 53.8% had FST IV-VI. Efficacy was comparable between regimens. The SM regimen resulted in significant improvements versus baseline in mean Investigator's Global Assessment of acne severity from 48 h through week 12 (p ≤ 0.001), as well as significant and sustained improvements from baseline in total acne lesion count, global postinflammatory hyperpigmentation/postinflammatory erythema, and oiliness. The SM Regimen was well tolerated at all time points, with mean scores below mild for all parameters; the Rx Regimen caused significantly more tightness/dry feeling at week 4 versus SM Regimen (p = 0.008). Subjects (> 96%) reported high satisfaction with the SM Regimen at all time points.
Conclusions: The SM Regimen reduced acne severity and skin oiliness, evening out skin tone without overdrying or irritating the skin.
{"title":"Efficacy and Tolerability of a Novel Cosmetic and Over-the-Counter Facial Acne Regimen Versus a Prescription Treatment.","authors":"Priscilla Huang, Olivia Supan, Cecilia L Pak, Rahul C Mehta, Elizabeth T Makino","doi":"10.1111/jocd.16568","DOIUrl":"https://doi.org/10.1111/jocd.16568","url":null,"abstract":"<p><strong>Background: </strong>The SkinMedica Acne Treatment Platform (SM Regimen) was formulated to treat acne without overdrying the skin. We evaluated efficacy and tolerability of the SM Regimen (including a novel 1% salicylic acid Acne Clarifying Cleanser and 2% salicylic acid Acne Treatment Lotion) versus a prescription formulation (Rx Regimen; including adapalene 0.1%/benzoyl peroxide 2.5%) in a diverse population of adults with mild to moderate facial acne.</p><p><strong>Methods: </strong>This single-center, double-blind, randomized study enrolled adults (18-45 years) with Fitzpatrick skin types (FST) I-VI. SM Regimen or Rx Regimen was applied topically to the entire face for 12 weeks. Assessments were conducted at 24 and 48 h and 4, 8, and 12 weeks.</p><p><strong>Results: </strong>Subjects (SM Regimen, n = 31; Rx Regimen, n = 23) were primarily female (90.7%) with mean age of 28.6 years; 53.8% had FST IV-VI. Efficacy was comparable between regimens. The SM regimen resulted in significant improvements versus baseline in mean Investigator's Global Assessment of acne severity from 48 h through week 12 (p ≤ 0.001), as well as significant and sustained improvements from baseline in total acne lesion count, global postinflammatory hyperpigmentation/postinflammatory erythema, and oiliness. The SM Regimen was well tolerated at all time points, with mean scores below mild for all parameters; the Rx Regimen caused significantly more tightness/dry feeling at week 4 versus SM Regimen (p = 0.008). Subjects (> 96%) reported high satisfaction with the SM Regimen at all time points.</p><p><strong>Conclusions: </strong>The SM Regimen reduced acne severity and skin oiliness, evening out skin tone without overdrying or irritating the skin.</p>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The robotic hair transplant technology, ARTAS, has a series of fine mechanical structure and an intelligent recognition system that allows it to independently select hair follicular units (FUs) and effectively harvest hair. After entering China in 2016, ARTAS has attracted the attention of hair transplant surgeons and hair loss patients given its advantages in a short learning curve and simple operation.
Objective: To compare the efficacy and safety between the ARTAS system and follicular unit excision (FUE) in the treatment of male androgenetic alopecia (AGA) and to further promote the improvement and upgrading of ARTAS technology concerning hair transplantation.
Methods: Thirteen Chinese male patients with Norwood-Hamilton II-IV AGA aged 25-35 years were enrolled in this study. The donor site of each patient was randomly divided into left and right regions, receiving ARTAS on one side and FUE on the other. Yield, transection, and discard rates of hair FUs from both sides were compared. Safety of the procedures in whole, as well as follow-up results were investigated and evaluated.
Results: The total yield rate on the ARTAS side was lower than on the FUE side (82.05% vs. 90.03%, p > 0.05); the total discard rate on the ARTAS side was higher than on the FUE side (10.71% vs. 5.46%, p < 0.05); the total transection rate on the ARTAS side was lower than on the FUE side (13.17% vs. 13.96%, p > 0.05). No significant difference was found in patient satisfaction (efficacy), and no side effects or complications were detected during or after all surgeries.
Conclusion: The current iteration of Robotic hair transplant technology is effective and safe, and can be recommended for AGA hair transplantation surgery.
背景：机器人植发技术ARTAS具有一系列精细的机械结构和智能识别系统，能够独立选择毛囊单位（FU）并有效采集头发。2016年进入中国后，ARTAS以其学习曲线短、操作简单等优势吸引了植发医生和脱发患者的关注：比较ARTAS系统和毛囊单位切除术（FUE）治疗男性雄激素性脱发（AGA）的疗效和安全性，进一步推动ARTAS技术在植发方面的改进和升级：方法：本研究选取了 13 名中国男性诺伍德-汉密尔顿 II-IV 型 AGA 患者，年龄在 25-35 岁之间。每位患者的供体部位被随机分为左右两个区域，一侧接受 ARTAS，另一侧接受 FUE。比较了两侧毛发FU的产量、横断率和丢弃率。对整个手术的安全性和随访结果进行了调查和评估：ARTAS一侧的总产量低于FUE一侧（82.05% vs. 90.03%，P > 0.05）；ARTAS一侧的总废弃率高于FUE一侧（10.71% vs. 5.46%，P 0.05）。在患者满意度（疗效）方面没有发现明显差异，所有手术期间或术后均未发现副作用或并发症：结论：目前的机器人植发技术有效且安全，可推荐用于 AGA 植发手术。
{"title":"A Comparative Study on the Application of Robotic Hair Restoration Technology Versus Traditional Follicular Unit Excision in Male Androgenetic Alopecia.","authors":"Yifei Zhu, Kai Yang, Jui-Ming Lin, Chunya Ni, Yue Zhang, Zheng Li, Qingmei Liu, Yinghui Zhou, Jinran Lin, Wenyu Wu","doi":"10.1111/jocd.16554","DOIUrl":"https://doi.org/10.1111/jocd.16554","url":null,"abstract":"<p><strong>Background: </strong>The robotic hair transplant technology, ARTAS, has a series of fine mechanical structure and an intelligent recognition system that allows it to independently select hair follicular units (FUs) and effectively harvest hair. After entering China in 2016, ARTAS has attracted the attention of hair transplant surgeons and hair loss patients given its advantages in a short learning curve and simple operation.</p><p><strong>Objective: </strong>To compare the efficacy and safety between the ARTAS system and follicular unit excision (FUE) in the treatment of male androgenetic alopecia (AGA) and to further promote the improvement and upgrading of ARTAS technology concerning hair transplantation.</p><p><strong>Methods: </strong>Thirteen Chinese male patients with Norwood-Hamilton II-IV AGA aged 25-35 years were enrolled in this study. The donor site of each patient was randomly divided into left and right regions, receiving ARTAS on one side and FUE on the other. Yield, transection, and discard rates of hair FUs from both sides were compared. Safety of the procedures in whole, as well as follow-up results were investigated and evaluated.</p><p><strong>Results: </strong>The total yield rate on the ARTAS side was lower than on the FUE side (82.05% vs. 90.03%, p > 0.05); the total discard rate on the ARTAS side was higher than on the FUE side (10.71% vs. 5.46%, p < 0.05); the total transection rate on the ARTAS side was lower than on the FUE side (13.17% vs. 13.96%, p > 0.05). No significant difference was found in patient satisfaction (efficacy), and no side effects or complications were detected during or after all surgeries.</p><p><strong>Conclusion: </strong>The current iteration of Robotic hair transplant technology is effective and safe, and can be recommended for AGA hair transplantation surgery.</p>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUNDAcne vulgaris presents a substantial clinical challenge due to its complex pathophysiology and significant impact on quality of life. Identification of novel therapeutic targets for acne using genetic tools can guide the development of more effective treatments.METHODSUtilizing a dataset comprising 35 559 Icelandic individuals, we performed proteomic analyses to quantify 4709 circulating proteins. We integrated these data with acne-specific genome-wide association studies (GWAS) encompassing 34 422 acne patients and 364 991 controls. Mendelian randomization (MR) analyses employed the TwoSampleMR tool and Summary-data-based Mendelian Randomization (SMR) to estimate the causal effects of identified proteins on acne risk. Colocalization analyses assessed the likelihood of shared genetic etiology between protein levels and acne using the "coloc" R package.RESULTSOur proteome-wide MR analysis initially identified 128 proteins potentially associated with acne risk. Following multiple testing corrections using the Benjamini-Hochberg method, fatty acid synthase (FASN) and tissue inhibitor of metalloproteinases 4 (TIMP4) remained significantly associated with acne risk. FASN exhibited a protective effect against acne (OR = 0.768, 95% CI: 0.676-0.872, p = 4.685E-05), while TIMP4 was associated with an increased risk (OR = 1.169, 95% CI: 1.103-1.241, p = 1.956E-07). Colocalization analysis supported a shared genetic basis for these protein-acne associations, with posterior probabilities indicating strong evidence of shared causal variants.CONCLUSIONOur findings highlight the utility of integrative genomic approaches in identifying potential therapeutic targets for acne. FASN and TIMP4, in particular, demonstrate strong potential as targets for therapeutic intervention, pending further validation through clinical research. These results offer a foundation for targeted acne treatment development, aligning with personalized medicine principles.
{"title":"Exploring Genetic Drug Targets in Acne Vulgaris: A Comprehensive Proteome-Wide Mendelian Randomization Study.","authors":"Ruyi Ju,Yuou Ying,Qiujun Zhou,Yi Cao","doi":"10.1111/jocd.16567","DOIUrl":"https://doi.org/10.1111/jocd.16567","url":null,"abstract":"BACKGROUNDAcne vulgaris presents a substantial clinical challenge due to its complex pathophysiology and significant impact on quality of life. Identification of novel therapeutic targets for acne using genetic tools can guide the development of more effective treatments.METHODSUtilizing a dataset comprising 35 559 Icelandic individuals, we performed proteomic analyses to quantify 4709 circulating proteins. We integrated these data with acne-specific genome-wide association studies (GWAS) encompassing 34 422 acne patients and 364 991 controls. Mendelian randomization (MR) analyses employed the TwoSampleMR tool and Summary-data-based Mendelian Randomization (SMR) to estimate the causal effects of identified proteins on acne risk. Colocalization analyses assessed the likelihood of shared genetic etiology between protein levels and acne using the \"coloc\" R package.RESULTSOur proteome-wide MR analysis initially identified 128 proteins potentially associated with acne risk. Following multiple testing corrections using the Benjamini-Hochberg method, fatty acid synthase (FASN) and tissue inhibitor of metalloproteinases 4 (TIMP4) remained significantly associated with acne risk. FASN exhibited a protective effect against acne (OR = 0.768, 95% CI: 0.676-0.872, p = 4.685E-05), while TIMP4 was associated with an increased risk (OR = 1.169, 95% CI: 1.103-1.241, p = 1.956E-07). Colocalization analysis supported a shared genetic basis for these protein-acne associations, with posterior probabilities indicating strong evidence of shared causal variants.CONCLUSIONOur findings highlight the utility of integrative genomic approaches in identifying potential therapeutic targets for acne. FASN and TIMP4, in particular, demonstrate strong potential as targets for therapeutic intervention, pending further validation through clinical research. These results offer a foundation for targeted acne treatment development, aligning with personalized medicine principles.","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BackgroundsWith the increasing demand for beauty and a healthy lifespan, studies regarding anti‐skin aging have drawn much more attention than ever before. Skin cellular senescence, the primary cause of skin aging, is characterized by a cell cycle arrest in proliferating cells along with a senescence‐associated secretory phenotype (SASP), which can be triggered by various internal or external stimuli.AimsRecent studies have made significant progress in the fields of anti‐senescence and anti‐aging. However, little is known about the roles and functions of natural compounds, particularly flavonoids, in skin cellular senescence studies.MethodsIn this study, using strategies including ionizing radiation (IR), senescence‐associated β galactosidase assay (SA‐β‐Gal), immunofluorescence (IF), flow cytometry, PCR array, as well as in vivo experiments, we investigated the effects and roles of troxerutin (Trx), a natural flavonoid, in skin keratinocyte senescence.ResultsWe found that Trx delays skin keratinocyte senescence induced by IR. Mechanistically, Trx protects the skin keratinocyte cells from senescence by alleviating reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and DNA damage caused by IR. In addition, Trx was also proved to relieve skin senescence and SASP secretion in vivo induced by IR stimulation.ConclusionsAltogether, our findings pointed to a new function of Trx in delaying stress‐induced skin keratinocyte senescence, and should thus provide theoretical foundations for exploring novel strategies against skin aging.
背景随着人们对美丽和健康寿命的要求越来越高，有关抗皮肤衰老的研究比以往任何时候都更受关注。皮肤细胞衰老是皮肤老化的主要原因，其特征是增殖细胞的细胞周期停滞以及衰老相关分泌表型（SASP），可由各种内部或外部刺激触发。然而，人们对天然化合物（尤其是类黄酮）在皮肤细胞衰老研究中的作用和功能知之甚少。方法在这项研究中，我们采用电离辐射（IR）、衰老相关β半乳糖苷酶测定（SA-β-Gal）、免疫荧光（IF）、流式细胞术、PCR阵列以及体内实验等策略，研究了天然类黄酮黄酮（Troxerutin，Trx）在皮肤角质细胞衰老中的影响和作用。从机理上讲，Trx 通过缓解红外引起的活性氧（ROS）积累、线粒体功能障碍和 DNA 损伤，保护皮肤角质细胞免于衰老。结论总之，我们的研究结果表明了 Trx 在延缓应激诱导的皮肤角质细胞衰老方面的新功能，从而为探索新的皮肤衰老策略提供了理论基础。
{"title":"Troxerutin Delays Skin Keratinocyte Senescence Induced by Ionizing Radiation Both In Vitro and In Vivo","authors":"Juping Chen, Jinghui Yang, Jiang Ma, Xiaoming Sun, Yuxuan Wang, Changjiao Luan, Jiaxiao Chen, Weili Liu, Qing Shan, Xingjie Ma","doi":"10.1111/jocd.16584","DOIUrl":"https://doi.org/10.1111/jocd.16584","url":null,"abstract":"BackgroundsWith the increasing demand for beauty and a healthy lifespan, studies regarding anti‐skin aging have drawn much more attention than ever before. Skin cellular senescence, the primary cause of skin aging, is characterized by a cell cycle arrest in proliferating cells along with a senescence‐associated secretory phenotype (SASP), which can be triggered by various internal or external stimuli.AimsRecent studies have made significant progress in the fields of anti‐senescence and anti‐aging. However, little is known about the roles and functions of natural compounds, particularly flavonoids, in skin cellular senescence studies.MethodsIn this study, using strategies including ionizing radiation (IR), senescence‐associated β galactosidase assay (SA‐β‐Gal), immunofluorescence (IF), flow cytometry, PCR array, as well as in vivo experiments, we investigated the effects and roles of troxerutin (Trx), a natural flavonoid, in skin keratinocyte senescence.ResultsWe found that Trx delays skin keratinocyte senescence induced by IR. Mechanistically, Trx protects the skin keratinocyte cells from senescence by alleviating reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and DNA damage caused by IR. In addition, Trx was also proved to relieve skin senescence and SASP secretion in vivo induced by IR stimulation.ConclusionsAltogether, our findings pointed to a new function of Trx in delaying stress‐induced skin keratinocyte senescence, and should thus provide theoretical foundations for exploring novel strategies against skin aging.","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BackgroundOral isotretinoin is the most effective systemic treatment for acne patients who fail to respond to other forms of therapies. However, hesitations and concerns regarding its side effect profile may detain the patients from treatment. This study aimed to develop and validate the Isotretinoin Hesitancy Scale (IHS) among acne patients.MethodsA cross‐sectional study was conducted with 100 acne patients who had not used isotretinoin previously. A 22‐item scale was created based on the related literature and expert opinions. The items of the scale related to beliefs and worries about isotretinoin were formatted with response options: agree, indecisive, and disagree. In this study, construct validity was tested with exploratory factor analysis, and reliability was tested with internal consistency and split‐half reliability.ResultsThe results of exploratory factor analysis indicated a three‐factor solution with a total of 14 items, explaining 57% of the total variance. The first factor (Hesitancy Related to Reversible Adverse Effects: 6 items) accounted for 30% of the variance, the second factor (Hesitancy Related to Irreversible Adverse Effects: 4 items) accounted for 16% of the variance and the third factor (Isotretinoin‐related Anxiety: 4 items) accounted 11% of the variance. The internal consistency of the three factors was calculated as 0.79, 0.78, and 0.72, respectively. The Cronbach's alpha score of the total scale was found to be 0.81, and split‐half reliability was found to be 0.87.ConclusionsThe IHS is the first scale that provides a valid and reliable assessment of isotretinoin hesitancy in acne patients. Eliminating isotretinoin hesitancy may reduce acne‐related clinical and psychosocial consequences.
{"title":"Development and Validation of the Isotretinoin Hesitancy Scale for Acne Vulgaris: A Preliminary Study","authors":"Esra Agaoglu, Imran Gokcen Yılmaz Karaman, Cennet Yastıbas Kacar, Hilal Kaya Erdogan, Talha Mutlu, Ayse Serap Karadag","doi":"10.1111/jocd.16589","DOIUrl":"https://doi.org/10.1111/jocd.16589","url":null,"abstract":"BackgroundOral isotretinoin is the most effective systemic treatment for acne patients who fail to respond to other forms of therapies. However, hesitations and concerns regarding its side effect profile may detain the patients from treatment. This study aimed to develop and validate the Isotretinoin Hesitancy Scale (IHS) among acne patients.MethodsA cross‐sectional study was conducted with 100 acne patients who had not used isotretinoin previously. A 22‐item scale was created based on the related literature and expert opinions. The items of the scale related to beliefs and worries about isotretinoin were formatted with response options: agree, indecisive, and disagree. In this study, construct validity was tested with exploratory factor analysis, and reliability was tested with internal consistency and split‐half reliability.ResultsThe results of exploratory factor analysis indicated a three‐factor solution with a total of 14 items, explaining 57% of the total variance. The first factor (Hesitancy Related to Reversible Adverse Effects: 6 items) accounted for 30% of the variance, the second factor (Hesitancy Related to Irreversible Adverse Effects: 4 items) accounted for 16% of the variance and the third factor (Isotretinoin‐related Anxiety: 4 items) accounted 11% of the variance. The internal consistency of the three factors was calculated as 0.79, 0.78, and 0.72, respectively. The Cronbach's alpha score of the total scale was found to be 0.81, and split‐half reliability was found to be 0.87.ConclusionsThe IHS is the first scale that provides a valid and reliable assessment of isotretinoin hesitancy in acne patients. Eliminating isotretinoin hesitancy may reduce acne‐related clinical and psychosocial consequences.","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Gold, Brian Biesman, Joel Cohen, Doris Day, David Goldberg, Sophie Guénin, Ted Lain, Todd Schlesinger, Ava Shamban, Suneel Chilukuri
Introduction
Real-world experience using an allograft adipose matrix (AAM) (Renuva) is presented as a series of seven cases demonstrating successful use of the matrix by nine expert cosmetic physicians across the United States. AAM is donated tissue that is aseptically processed without terminal irradiation into a transplantable adipose matrix that functions as a natural, versatile, and nonimmunogenic cushioning and volume-restoring tissue. When injected, the adipose matrix is replaced with the body's own fat cells and provides the cellular scaffold required for volume restoration and retention.
Methods
Nine expert dermatologists were selected to share and discuss real-world patient cases using AAM. The experts discussed a variety of cases and selected 7 cases that demonstrated successful, novel use of AAM to present in this manuscript.
Results
Experts agreed that the novel AAM is an easy-to-use, effective, and safe alternative to traditional fillers and fat grafting.
Conclusion
The use of the AAM is recommended for the face, hands, and other adipose tissue-containing parts of the body. The presented real-world cases provide guidance on how to identify ideal candidates to ensure optimal volume restoration results.
{"title":"Real-World Clinical Experience With an Allograft Adipose Matrix for Replacing Volume Loss in Face, Hands, and Body","authors":"Michael Gold, Brian Biesman, Joel Cohen, Doris Day, David Goldberg, Sophie Guénin, Ted Lain, Todd Schlesinger, Ava Shamban, Suneel Chilukuri","doi":"10.1111/jocd.16579","DOIUrl":"https://doi.org/10.1111/jocd.16579","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Real-world experience using an allograft adipose matrix (AAM) (Renuva) is presented as a series of seven cases demonstrating successful use of the matrix by nine expert cosmetic physicians across the United States. AAM is donated tissue that is aseptically processed without terminal irradiation into a transplantable adipose matrix that functions as a natural, versatile, and nonimmunogenic cushioning and volume-restoring tissue. When injected, the adipose matrix is replaced with the body's own fat cells and provides the cellular scaffold required for volume restoration and retention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Nine expert dermatologists were selected to share and discuss real-world patient cases using AAM. The experts discussed a variety of cases and selected 7 cases that demonstrated successful, novel use of AAM to present in this manuscript.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Experts agreed that the novel AAM is an easy-to-use, effective, and safe alternative to traditional fillers and fat grafting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The use of the AAM is recommended for the face, hands, and other adipose tissue-containing parts of the body. The presented real-world cases provide guidance on how to identify ideal candidates to ensure optimal volume restoration results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.16579","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142244786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Gold, Brian Biesman, Joel L. Cohen, David J. Goldberg, Sophie Guenin, Todd Schlesinger, Zaki Taher
Background
Medical aesthetic procedures for facial rejuvenation with laser and energy-based devices (EBDs) are rapidly increasing. The following cases highlight real-life experience using a multi-modality system with various handpieces that combine intense pulsed light (IPL), laser hair removal (808 diode), high-intensity focused ultrasound (HIFU), radiofrequency microneedling (RFM), and thermal radiofrequency (RF) for antiaging and rejuvenation treatment. Laser and RFM treatments may improve skin conditions by inducing cutaneous changes that remodel the skin matrix.
Methods
Six physicians who treat patients for skin rejuvenation reported on clinical cases from their practice using a multi-modality system with various handpieces.
Results
During the meeting, the advisors discussed 15 cases and agreed to select seven patients with different ages and skin phototypes receiving various treatments for photodamage of the face, neck, and décolleté. The advisors discussed why they selected the case, previous treatment, type of treatment, results, and clinical pearls.
Conclusion
Sharing best practices in medical aesthetics using combination treatments on a single multi-modality energy-based device such as laser and MRF for facial, neck, and chest skin may support healthcare providers treating patients for skin rejuvenation to improve clinical outcomes.
{"title":"Real-World Experience Using a Multi-Modality System using Intense Pulsed Light, Radiofrequency Microneedling, High-Intensity Focused Ultrasound, or Thermal Radiofrequency, 808, HIFU for Skin Rejuvenation Treatment","authors":"Michael Gold, Brian Biesman, Joel L. Cohen, David J. Goldberg, Sophie Guenin, Todd Schlesinger, Zaki Taher","doi":"10.1111/jocd.16577","DOIUrl":"https://doi.org/10.1111/jocd.16577","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Medical aesthetic procedures for facial rejuvenation with laser and energy-based devices (EBDs) are rapidly increasing. The following cases highlight real-life experience using a multi-modality system with various handpieces that combine intense pulsed light (IPL), laser hair removal (808 diode), high-intensity focused ultrasound (HIFU), radiofrequency microneedling (RFM), and thermal radiofrequency (RF) for antiaging and rejuvenation treatment. Laser and RFM treatments may improve skin conditions by inducing cutaneous changes that remodel the skin matrix.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Six physicians who treat patients for skin rejuvenation reported on clinical cases from their practice using a multi-modality system with various handpieces.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the meeting, the advisors discussed 15 cases and agreed to select seven patients with different ages and skin phototypes receiving various treatments for photodamage of the face, neck, and décolleté. The advisors discussed why they selected the case, previous treatment, type of treatment, results, and clinical pearls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Sharing best practices in medical aesthetics using combination treatments on a single multi-modality energy-based device such as laser and MRF for facial, neck, and chest skin may support healthcare providers treating patients for skin rejuvenation to improve clinical outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.16577","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142244782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ObjectiveEnvironmental factors are important in the generation or aggravation of sensitive skin syndrome (SSS). Creams can be useful for patients with SSS, particularly when triggering factors cannot be avoided. Several clinical studies have investigated the safety and efficacy of specific creams in patients with SSS, but the majority were assessed with a single type of triggering factor and were non‐comparative. Therefore, this study's aim was to investigate, the benefit of a specific dermo‐cosmetic product in response to physical and chemical factors in subjects with SSS.MethodsThree clinical studies were performed on subjects presenting SSS. The physical impact was assessed in a stripping test, and in a randomized intra‐individual study with a newly developed heat–cold stress model. To assess chemical factors, a capsaicin test on the nasolabial fold was performed.ResultsThe product significantly reduced the increase in skin microcirculation caused by stripping after 30 min versus. The untreated condition (45.8% vs. 62.0%; p < 0.01). Immediately and at D28, the product induced a significant increase in skin hydration even after a heat–cold stress, while the overall score of unpleasant symptoms significantly decreased compared with the control (8.1 vs. 10.7 and 3.7 vs. 8.0, respectively; p < 0.01). Regarding chemical factors, a significant difference in the sensation intensity (p < 0.001) was observed after capsaicin stress, also in terms of the sensation duration due to the product application versus the control (192 s vs. 403 s; p < 0.001).ConclusionThese studies show that topical application of a dermo‐cosmetic product can prevent unpleasant symptoms and improve the skin state in SSS exposed to physical and chemical triggering factors.
{"title":"Management of triggering factor effects in sensitive skin syndrome with a dermo‐cosmetic product","authors":"Helena Polena, Arnaud Fontbonne, Elise Abric, Guillaume Lecerf, Marlène Chavagnac‐Bonneville, Alain Moga, Nathalie Ardiet, Sandra Trompezinski, Michèle Sayag","doi":"10.1111/jocd.16529","DOIUrl":"https://doi.org/10.1111/jocd.16529","url":null,"abstract":"ObjectiveEnvironmental factors are important in the generation or aggravation of sensitive skin syndrome (SSS). Creams can be useful for patients with SSS, particularly when triggering factors cannot be avoided. Several clinical studies have investigated the safety and efficacy of specific creams in patients with SSS, but the majority were assessed with a single type of triggering factor and were non‐comparative. Therefore, this study's aim was to investigate, the benefit of a specific dermo‐cosmetic product in response to physical and chemical factors in subjects with SSS.MethodsThree clinical studies were performed on subjects presenting SSS. The physical impact was assessed in a stripping test, and in a randomized intra‐individual study with a newly developed heat–cold stress model. To assess chemical factors, a capsaicin test on the nasolabial fold was performed.ResultsThe product significantly reduced the increase in skin microcirculation caused by stripping after 30 min versus. The untreated condition (45.8% vs. 62.0%; <jats:italic>p</jats:italic> < 0.01). Immediately and at D28, the product induced a significant increase in skin hydration even after a heat–cold stress, while the overall score of unpleasant symptoms significantly decreased compared with the control (8.1 vs. 10.7 and 3.7 vs. 8.0, respectively; <jats:italic>p</jats:italic> < 0.01). Regarding chemical factors, a significant difference in the sensation intensity (<jats:italic>p</jats:italic> < 0.001) was observed after capsaicin stress, also in terms of the sensation duration due to the product application versus the control (192 s vs. 403 s; <jats:italic>p</jats:italic> < 0.001).ConclusionThese studies show that topical application of a dermo‐cosmetic product can prevent unpleasant symptoms and improve the skin state in SSS exposed to physical and chemical triggering factors.","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142269800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yihan Zhang, Yansi Lyu, Tingyin Lin, Luotai Chen, Zhuolin Liu, Yanting Ou, Xiangwen Xu, Mengfan Wu, Lin Luo, Jun Feng, Dandan Liu
BackgroundThe field of cosmetic filler injection has experienced rapid development over the past two decades, especially in facial augmentation utilizing hyaluronic acid (HA) fillers. Gram‐negative bacteria are found to be the main pathogens of infective nodules after HA injection. The occurrence of cutaneous infections attributed to Serratia marcescens is exceedingly rare and predominantly noted in patients with compromised immune systems.AimsTo summarize the clinical features, diagnosis, and treatment of subcutaneous infection caused by Serratia marcescens following hyaluronic acid injection.Patients/MethodsA rare case of cutaneous Serratia marcescens infection following hyaluronic acid injection was presented. A comprehensive review of the published literature describing the management of skin infection caused by S. marcescens in immunocompetent patients was then conducted, which encompassed three case series and eight case reports published between 1999 and 2017. Data extraction included information on authors, gender, age, signs and symptoms, previous treatment, corresponding management strategies, and follow‐up duration.ResultsSerratia marcescens were isolated in abscesses (n = 6, 35.29%), painful nodules (n = 2, 11.76%), ulcers (n = 6, 35.29%), and others (n = 3, 17.65%). In cases providing salvage plans (n = 11), quinolones were shown to be the most effective antibiotics for salvage, with eight full recoveries (72.73%), and trimethoprim‐sulfamethoxazole was the second most useful antibiotic (18.18%).ConclusionsWith the help of pathogen examination and drug‐sensitive tests, sensitive aminoglycosides, quinolone (especially moxifloxacin), or TMP‐SMX for at least 2 weeks can be considered as the first‐line treatment of late subcutaneous infection caused by Serratia marcescens following hyaluronic acid injection.
{"title":"Late Subcutaneous Infection Caused by Serratia marcescens Following Hyaluronic Acid Injection: A Case Report and Systemic Review","authors":"Yihan Zhang, Yansi Lyu, Tingyin Lin, Luotai Chen, Zhuolin Liu, Yanting Ou, Xiangwen Xu, Mengfan Wu, Lin Luo, Jun Feng, Dandan Liu","doi":"10.1111/jocd.16571","DOIUrl":"https://doi.org/10.1111/jocd.16571","url":null,"abstract":"BackgroundThe field of cosmetic filler injection has experienced rapid development over the past two decades, especially in facial augmentation utilizing hyaluronic acid (HA) fillers. Gram‐negative bacteria are found to be the main pathogens of infective nodules after HA injection. The occurrence of cutaneous infections attributed to <jats:italic>Serratia marcescens</jats:italic> is exceedingly rare and predominantly noted in patients with compromised immune systems.AimsTo summarize the clinical features, diagnosis, and treatment of subcutaneous infection caused by <jats:italic>Serratia marcescens</jats:italic> following hyaluronic acid injection.Patients/MethodsA rare case of cutaneous <jats:italic>Serratia marcescens</jats:italic> infection following hyaluronic acid injection was presented. A comprehensive review of the published literature describing the management of skin infection caused by <jats:italic>S. marcescens</jats:italic> in immunocompetent patients was then conducted, which encompassed three case series and eight case reports published between 1999 and 2017. Data extraction included information on authors, gender, age, signs and symptoms, previous treatment, corresponding management strategies, and follow‐up duration.Results<jats:italic>Serratia marcescens</jats:italic> were isolated in abscesses (<jats:italic>n</jats:italic> = 6, 35.29%), painful nodules (<jats:italic>n</jats:italic> = 2, 11.76%), ulcers (<jats:italic>n</jats:italic> = 6, 35.29%), and others (<jats:italic>n</jats:italic> = 3, 17.65%). In cases providing salvage plans (<jats:italic>n</jats:italic> = 11), quinolones were shown to be the most effective antibiotics for salvage, with eight full recoveries (72.73%), and trimethoprim‐sulfamethoxazole was the second most useful antibiotic (18.18%).ConclusionsWith the help of pathogen examination and drug‐sensitive tests, sensitive aminoglycosides, quinolone (especially moxifloxacin), or TMP‐SMX for at least 2 weeks can be considered as the first‐line treatment of late subcutaneous infection caused by <jats:italic>Serratia marcescens</jats:italic> following hyaluronic acid injection.","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号